TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06362369: A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Sponsor: 7 Hills Pharma, LLC · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 126 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT06362369 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06362369 Rescue Dossier →